Adverse drug reactions observed during DOTS

Journal of Communicable Diseases

Volumn 36, Issue 4, 2004, Pages 251-259

  Dhingra, V K ^a   Rajpal, S ^a   Aggarwal, Nishi ^a   Aggarwal, J K ^a   Shadab, Khan ^a   Jain, S K ^b  

^a New Delhi Tuberculosis Centre   (India)

^b NATIONAL INSTITUTE OF COMMUNICABLE DISEASES   (India)

Author keywords

Adverse drug reactions; DOTS; RNTCP; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HUMAN; INDIA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PUBLIC HEALTH; TUBERCULOSIS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HUMANS; INDIA; ISONIAZID; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PATIENT COMPLIANCE; PYRAZINAMIDE; RIFAMPIN; STREPTOMYCIN; TUBERCULOSIS;

EID: 30944437845     PISSN: 00195138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Performance of RNTCP; India, First quarter 2003, Central TB Division, Ministry of Health & Family Welfare, Nirman Bhawan, New Delhi-110 011
2. Diagnosis and treatment of tuberculosis - Revised National TB Control Programme. Training course for Medical Officers 1998; Module 1-4 Central TB Division, Ministry of Health & Family Welfare, New Delhi-110 011.
3. Toman K. Tuberculosis case finding and chemotherapy World Health Organisation, Geneva 2002.
4. Singh MM, Dhingra VK. Essentials of tuberculosis for practitioners of modern medicine. New Delhi. TB Association of India. 2003.
5. Addington WW. Patient compilance: the most serious remaining problem in the control of tuberculosis in the United States. Chest 1979; 76: 750-756.
6. Snider DE. Jr. Improving patient compliance tuberculosis treatment programme. US Department of Health and Human Services, Atlanta, Ga, pp. 1-18.
7. Sbarbaro JA. Public health aspects of tuberculosis in supervision of therapy. Clin Chest Med 1980; 1: 253-263.
8. Combs DL, O'Brien RJ and Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990; 112: 397-406.
9. Hong Kong Chest Service/British Medical Research Council. First report: Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981; 1: 171-174.
10. Hong Kong Chest Service/Tuberculosis Research Centre Madras/British Medical Research Council. A controlled trial of 3-month, 4-month and 6-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis. Results at 5 years. Am Rev Respir Dis 1989; 139: 871-876.
11. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2,4 and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide. Results at 30 months. Am Rev Respir Dis 1991; 143: 700-706.
12. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R eds. Principles & practice of infectious diseases. Philadelphia: Churchill Livingstone 2000; 307-336.
13. Iseman MD. Tuberculosis chemotherapy including directly observed therapy. A clinician's guide to tuberculosis. Philadelphia: Lippincott Williams & Wilkins 2000; 271-321.
14. nd Edn.; Philadelphia, USA: Lippincott Williams & Wilkins 2004; 823-833.
15. Blajchman MA, Lowry RC, Pettit JE, et al. Rifampicin - induced immune thrombocytopenia. BMJ 1970; 3:24-26.
16. Singapore Tuberculosis Service/British Medical Research Council. Controlled trial of intermittent regimens of rifampcin plus isoniazid for pulmonary tuberculosis in Singapore. The results upto 30 months. Am Rev Respir Dis 1977; 116: 807-820.
17. nd Edn.; Philadelphia, USA: Lippincott Williams & Wilkins 2004; 739-758.